What is DiaMedica Therapeutics Inc. (DMAC)?

DiaMedica Therapeutics Inc. (DMAC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of DMAC?

The current price of DMAC is $9.82. Prices are updated in real time on Stocks360.

What is DMAC's price-to-earnings (PE) ratio?

DMAC's trailing twelve-month PE ratio is -13.64, based on current price and earnings per share data available on Stocks360.

What is DMAC's market capitalization?

DMAC's market capitalization is $529,550,345.00, placing it in the small-cap tier.

DiaMedica Therapeutics Inc. (DMAC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.82

Market Cap

$529.55M

PE (TTM)

-13.64

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.91

Day Range

$8.60 – $10.13

52-wk Range

$5.25 – $10.42

Avg Volume

N/A

Volume

519.65K

DiaMedica Therapeutics Inc. (DMAC) is a publicly traded company in the Healthcare sector. Latest price: $9.82. Market cap $529.55M. Trailing PE -13.64. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $6.69 2026-10-28 · $9.82 (+46.79%)

Earnings

Most Recent

Aug 10, 2026

EPS $-0.19 vs est. $-0.20

Beat by $0.01

Next Earnings

Nov 11, 2026

EPS estimate $-0.20

Proprietary Signals

Signal snapshot temporarily unavailable.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-13.64×
P/S (TTM)	0.00×
P/B	13.80×
PEG	3.17×
P/FCF (TTM)	-16.76×
EV / EBITDA	-14.00×
EV / Sales	0.00×
Earnings Yield	-7.09%
Free Cash Flow Yield	-5.97%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$524.61M
Net Income (TTM)	-$37.56M
Free Cash Flow (TTM)	-$31.60M
Net Debt	-$4.94M
Working Capital	$37.72M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-77.68%
Return on Invested Capital	-100.87%